Forfar minor injury unit facing axe in Angus centralisation plan
The Whitehills Health and Community Care Centre facility is one of two remaining district MIIUs.
But it is now under threat after health chiefs identified a centralised Angus service at Arbroath Infirmary as their preferred option in a major service redesign.
They say the new plans would bring enhanced Community Treatment and Care (CTAC) services for long-term conditions, wound care and blood sampling across the district.
However, the return of an MIIU to Montrose – closed in 2022 – has been ruled out.
The centralisation option follows an initial round of public consultation over Angus-wide MIIU services.
In February, Angus integration joint board (IJB) considered a strategic vision report on MIIU provision.
It agreed to an initial round of public consultation.
A survey presented four options:
There were almost 2,200 responses. One of the main themes was in relation to extended opening times.
Angus Health and Social Care Partnership say that over a seven-day average, 21 people a day require MIIU treatment at either Forfar or Arbroath.
Most have a limb injury that is likely to need an X-ray.
And on average a person goes to MIIU once every 10 years.
A new survey has now been launched to gauge opinion on the preferred option.
AHSCP says it will look at whether the centralised Arbroath MIIU and enhanced CTAC plan is workable and meets local needs.
It rejected the idea the changes are all about saving money.
'The proposed review is clinically driven and aims to deliver high-quality, patient-centred care,' said AHSCP.
'Enhanced collaboration between minor injury and CTAC services aims to optimise the use of resources and ensure the long-term sustainability of services.'
A final decision on the changes is expected to be made by Angus IJB in June.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Herald Scotland
a day ago
- The Herald Scotland
Aberdeen University study to probe link between anorexia and autism
Researchers from the University of Aberdeen are seeking volunteers from the autistic community to undergo a brain scan with the aim of better understanding the relationship between brain structure, eating disorder symptoms and autistic 'masking' behaviour. Masking is a behaviour exhibited by autistic individuals, where specific behaviours are consciously or unconsciously concealed to fit into social situations normally, or to avoid negative responses from others. However, masking, particularly as a long-term strategy, can produce negative effects on autistic people's mental health and well-being. Concerns have been raised about the effectiveness and potential harms of traditional eating disorder treatments for the autistic community, leading to calls to develop new autistic-affirming approaches to eating disorder treatments. Aberdeen University (Image: NQ) Autistic individuals who have a current or past diagnosis of anorexia nervosa, or those who have no history of an eating disorder, are needed for the pioneering study which hopes to provide insights which can be used to better tailor future treatments. The study is being carried out and supervised by Dr Michelle Sader who is postdoctoral research fellow for the Eating Disorders and Autism Collaborative (EDAC) at the University of Aberdeen. EDAC is a UK-wide collaborative network seeking to bridge the gap between autism and eating disorders research through a lived experience lens. Dr Sader said: 'In our previous work, autistic collaborators highlighted the importance of investigating how masking behaviour relates to eating disorder development or maintenance in autistic people. 'Taking part in this research would not only help us understand what regions of the brain may be associated with autistic masking, but also whether masking is differently associated with, or plays a different role in autistic individuals with an eating disorder. Dr Sader added: 'Around 27 per cent of autistic people display symptoms of eating disorders, and individuals with more autistic characteristics tend to experience more severe eating disorder symptoms. 'There is a significant overlap between autism and eating disorders which is not yet fully understood, and we need to change that. 'By taking part, volunteers will be helping shape a future with more appropriate and effective support for autistic individuals.'
North Wales Chronicle
2 days ago
- North Wales Chronicle
Government partners with Mounjaro maker to tackle obesity
The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities. Over the next three years, about 240,000 patients are expected to be eligible for the treatment.
Leader Live
2 days ago
- Leader Live
Government partners with Mounjaro maker to tackle obesity
The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities. Over the next three years, about 240,000 patients are expected to be eligible for the treatment.
